Clinical Trial Update: GIP: Glucose-dependent Insulinotropic Peptide [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for GIP (glucose-dependent insulinotropic peptide) in Type 2 diabetes. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GIP (Glucose-dependent Insulinotropic Peptide) (glucose-dependent insulinotropic peptide)

Snippet

Sponsor: National Institute on Aging (NIA) | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED